Immunotherapy for Cancer: How It Works and Who May Benefit

Immunotherapy for cancer is a group of treatments that helps the immune system recognize and attack cancer cells more effectively. It can be highly beneficial for selected patients, but the best option depends on cancer type, stage, biomarkers, overall health, and previous treatments.

Overview

Immunotherapy for cancer is a treatment approach that uses the body’s immune system to help detect, control, and sometimes destroy cancer cells. The immune system normally identifies many abnormal cells, but cancer can develop ways to hide from immune attack or weaken immune responses. Immunotherapy aims to restore or improve this natural defense.

Unlike chemotherapy, which generally targets rapidly dividing cells, or radiation therapy, which treats a defined area, immunotherapy works through immune pathways. Some treatments remove the “brakes” that prevent immune cells from attacking cancer, while others train or engineer immune cells to recognize specific cancer targets. Because of this, responses can vary greatly from one person to another.

Immunotherapy has changed the treatment landscape for several cancers, including melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancers, some blood cancers, and certain colorectal and gynecologic cancers with specific molecular features. However, it is not appropriate for every patient or every tumor. A careful oncology evaluation is needed to determine whether it is likely to help and how it should fit into the overall treatment plan.

How Immunotherapy Works

The immune system includes many specialized cells, such as T cells, B cells, natural killer cells, and antigen-presenting cells. These cells communicate through chemical signals and use surface markers to distinguish healthy tissue from threats. Cancer cells may avoid this surveillance by changing their appearance, creating an immune-suppressing environment, or using checkpoint pathways that tell immune cells to stand down.

One of the best-known forms of cancer immunotherapy is immune checkpoint inhibition. Checkpoint proteins, such as PD-1, PD-L1, and CTLA-4, help prevent the immune system from overreacting. Some cancers use these proteins to escape immune attack. Checkpoint inhibitor medicines block these signals, allowing immune cells to recognize and attack cancer more effectively.

Other immunotherapies work in different ways. Some monoclonal antibodies attach to cancer cells and mark them for immune destruction. CAR T-cell therapy involves collecting a patient’s T cells, modifying them in a laboratory to recognize a cancer target, and returning them to the patient. Cancer vaccines, cytokines, and immune cell therapies are also used in selected situations or studied in clinical trials.

Types of Cancer Immunotherapy

Immunotherapy is not a single treatment. It is a broad category that includes several therapies with different mechanisms, schedules, benefits, and risks. The oncology team selects a type based on the cancer diagnosis, laboratory results, prior treatments, and the patient’s overall condition.

• Immune checkpoint inhibitors: These medicines help T cells stay active against cancer by blocking checkpoint pathways such as PD-1, PD-L1, or CTLA-4.
• CAR T-cell therapy: This personalized cell therapy is mainly used for certain leukemias, lymphomas, and multiple myeloma, and is being studied in other cancers.
• Monoclonal antibodies: Some antibodies directly target cancer cells, while others help the immune system identify them or deliver treatment to a tumor target.
• Cancer vaccines: These may help the immune system recognize cancer-associated antigens. Some are used for prevention, while therapeutic vaccines are used or studied for treatment.
• Cytokines and immune modulators: These substances influence immune activity and may be considered in selected cancer types.

Immunotherapy may be given as an infusion, injection, oral medication, or cellular therapy procedure, depending on the treatment type. It may be used before surgery to shrink a tumor, after surgery to reduce recurrence risk, for advanced or metastatic disease, or in combination with other treatments. The timing and goals should always be discussed clearly with the treating oncologist.

Who May Benefit

Patients most likely to benefit from immunotherapy are those whose cancer has features that make it visible or vulnerable to immune attack. These features can include certain biomarkers, genetic changes, or immune activity within the tumor. For example, some cancers with high microsatellite instability or mismatch repair deficiency may respond well to immune checkpoint inhibitors, regardless of where the cancer started.

Doctors may order tests such as PD-L1 expression, MSI or MMR testing, tumor mutational burden, next-generation sequencing, or other pathology and molecular studies. These tests do not guarantee that immunotherapy will or will not work, but they help guide treatment decisions. Imaging, biopsy results, blood tests, symptoms, performance status, and previous therapy responses also matter.

Immunotherapy may be considered in early-stage, locally advanced, recurrent, or metastatic cancer depending on established treatment guidelines and individual factors. Some patients receive it as first-line treatment, while others receive it after chemotherapy, targeted therapy, radiation, or surgery. In some cases, participation in a clinical trial may provide access to newer immune-based strategies under careful monitoring.

Not all patients are good candidates. People with active autoimmune diseases, organ transplants, uncontrolled infections, severe frailty, or certain organ problems may need special assessment because immune stimulation can carry additional risks. The decision is individualized, balancing potential benefit, possible side effects, treatment goals, and quality of life.

Treatment Process and Monitoring

Before starting immunotherapy, the oncology team reviews the diagnosis, cancer stage, pathology report, molecular test results, medical history, medications, allergies, and previous treatments. Baseline blood tests and imaging are often performed. Patients are also asked about autoimmune conditions, lung disease, liver disease, hormone disorders, infections, and transplant history because these can influence safety.

During treatment, appointments may include physical examination, symptom review, laboratory testing, and periodic scans. Some immunotherapies are given every few weeks, while cellular therapies such as CAR T-cell therapy require a more complex process that includes cell collection, manufacturing, conditioning treatment, infusion, and close monitoring. The exact pathway varies by cancer type and treatment plan.

Response to immunotherapy can look different from response to other cancer treatments. Some tumors shrink quickly, while others stabilize over time. Rarely, scans may appear worse before improvement occurs because immune cells have entered the tumor, a pattern sometimes called pseudoprogression. However, true progression is more common than pseudoprogression, so oncologists interpret imaging alongside symptoms, examination findings, and follow-up scans.

Open communication is essential throughout treatment. Patients should tell their care team about new symptoms, even if they seem mild or unrelated. Early recognition allows side effects to be managed promptly and may help patients continue treatment safely when appropriate.

Possible Side Effects

Immunotherapy side effects differ from those of chemotherapy because they are often related to immune activation. When the immune system becomes more active, it may sometimes affect healthy organs. These reactions are called immune-related adverse events and can occur during treatment or, less commonly, weeks to months after treatment ends.

Common or important symptoms to report include persistent diarrhea, abdominal pain, new cough, shortness of breath, chest discomfort, yellowing of the skin or eyes, severe fatigue, headaches, vision changes, skin rash, itching, joint pain, or changes in urination. Hormone-producing glands may also be affected, leading to thyroid, adrenal, or pituitary problems. Blood tests may detect some changes before symptoms become obvious.

Many immune-related side effects are manageable when identified early. Depending on severity, the care team may pause immunotherapy, prescribe anti-inflammatory medicines such as corticosteroids, replace affected hormones, involve organ specialists, or provide supportive care. Patients should not self-treat serious symptoms or stop prescribed medicines without medical advice.

CAR T-cell therapy and some other cellular therapies can have distinct risks, such as cytokine release syndrome or neurological symptoms, which require specialized monitoring. For this reason, these treatments are given in centers with trained teams and established safety protocols. Patients and caregivers are educated about warning signs before discharge and follow-up.

Prevention, Self-Care, and Questions to Ask

There is no lifestyle change that can guarantee immunotherapy will work, but good general health can support treatment tolerance and recovery. Patients are encouraged to follow their oncology team’s advice about nutrition, hydration, activity, sleep, vaccinations, infection precautions, and management of other medical conditions. Any supplements, herbal products, or over-the-counter medicines should be discussed before use because they may interact with cancer treatment or affect the immune system.

Patients can prepare for appointments by keeping a symptom diary and bringing a current medication list. It is helpful to ask which type of immunotherapy is being recommended, what goal it has, how success will be measured, what side effects require urgent contact, and whether biomarker testing has been completed. Patients may also ask whether immunotherapy will be combined with other treatments and how it may affect work, travel, fertility, or daily routines.

Emotional support is also an important part of cancer care. Uncertainty about response, scan results, and side effects can be stressful. Counseling, patient education, support groups, rehabilitation services, and palliative care support can help patients maintain comfort, function, and quality of life at any stage of treatment.

When to See a Doctor

A person diagnosed with cancer should discuss immunotherapy with a qualified oncologist, especially if the cancer is advanced, recurrent, difficult to treat, or known to have biomarkers that may predict response. A second opinion may be useful when treatment choices are complex or when clinical trial options are being considered. The decision should be based on current evidence, the patient’s goals, and a full review of medical records.

Patients already receiving immunotherapy should contact their care team promptly for new or worsening symptoms, including breathing problems, severe or persistent diarrhea, high fever, confusion, severe weakness, chest pain, yellowing of the skin or eyes, intense headache, or sudden vision changes. These symptoms do not always mean a serious complication, but they should be assessed quickly because early treatment can make management easier.

International patients may also need coordination of pathology review, molecular testing, treatment scheduling, and follow-up planning. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat many cancers, including cases where immunotherapy is part of the care plan. Patients should bring pathology reports, imaging, prior treatment summaries, and medication lists to support an accurate consultation.

Frequently asked questions

Is immunotherapy the same as chemotherapy?

No. Chemotherapy generally acts directly on rapidly dividing cells, while immunotherapy helps the immune system recognize or attack cancer cells. Both treatments can be effective in the right setting, and they are sometimes used together.

How long does immunotherapy take to work?

The timing varies by cancer type, treatment type, and individual response. Some patients show improvement within weeks or months, while others have stable disease before a clear response is seen. Doctors monitor progress with symptoms, examinations, blood tests, and imaging.

Can immunotherapy cure cancer?

In some cancers and some patients, immunotherapy can lead to long-lasting remission. However, it does not work for everyone, and it should not be described as a guaranteed cure. The expected benefit depends on the diagnosis, stage, biomarkers, and overall treatment plan.

What tests show whether immunotherapy may help?

Doctors may request tests such as PD-L1 expression, MSI or MMR status, tumor mutational burden, and broader genetic profiling. These tests help estimate the chance of benefit but cannot predict response with certainty. Clinical factors and imaging findings are also important.

Are immunotherapy side effects permanent?

Many side effects improve with early recognition and appropriate treatment. Some hormone-related effects, such as thyroid or adrenal changes, may require long-term medication. Patients should report symptoms promptly so the care team can act before problems become more severe.

Can a patient receive immunotherapy after surgery or radiation?

Yes, in selected cancers immunotherapy may be used before surgery, after surgery, after radiation, or together with other treatments. The timing depends on the cancer type, stage, biomarker results, and treatment goals. An oncologist can explain whether this approach is suitable.

References

• National Cancer Institute
• American Society of Clinical Oncology
• European Society for Medical Oncology
• World Health Organization
• U.S. Food and Drug Administration

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.